背景:ALK参与D2R的摄取和调节,在不同脑区表达的G蛋白偶联受体。因此,了解ALK抑制剂与癫痫发作之间的关系至关重要。本研究调查了ALK抑制剂与癫痫发作之间的关系。
方法:本研究通过使用FAERS的不成比例分析来调查ALK抑制剂与癫痫发作之间的关系。目标药物是ALK抑制剂克唑替尼,ceritinib,阿列替尼,布加替尼,还有Lorlatinib.所涵盖的癫痫发作定义为HLGT:\'\'癫痫发作(包括亚型)\'\'包括HLT:\'\'癫痫发作和癫痫发作疾病NEC。\'\'这项研究使用了IC,信号分数,作为不成比例分析的贝叶斯统计方法。
结果:每种ALK抑制剂的\'\'癫痫发作和癫痫发作障碍的信号评分NEC\'\'为克唑替尼(IC:-0.00052,95%CrI:-0.38-0.27),色瑞替尼(IC:1.18,95%CrI:0.68-1.54),阿来替尼(IC:0.68,95%CrI:0.19-1.02),布加替尼(IC:1.04,95%CrI:0.32-1.54),和氯拉替尼(IC:0.82,95%CrI:0.11-1.32)。另一方面,\'\'广义强直阵挛性癫痫发作\'\',\'\'部分单纯性癫痫发作NEC,\'\'\'\'\'失神癫痫发作,\'\'和\'\'部分复杂发作\'\'没有或很少报告病例,没有检测到信号.
结论:据我们所知,这是第一份使用上市后监测数据评估ALK抑制剂与癫痫发作之间关系的报告.这些结果表明,色瑞替尼,阿列替尼,布加替尼,和lorlatinib,是高度脑迁移的药物,与癫痫发作有关。
BACKGROUND: Anaplastic lymphoma kinase (ALK) has been to be involved in the uptake and regulation of dopamine 2 receptor (D2R), a G protein-coupled receptor expressed in various brain regions. Therefore, it is crucial to understand the relationship between ALK inhibitors and seizures is an important issue. This study investigated the relationship between ALK inhibitors and seizures.
METHODS: This study investigated the relationship between ALK inhibitors and seizures through a disproportionality analysis using the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). The target drugs were the ALK inhibitors crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib. The seizures covered were defined high-level group term (HLGT): \"Seizures (incl. subtype)\" including high-level term (HLT): \"seizures and seizure disorders NEC.\" This study used the information component (IC), a signal score, as a Bayesian statistical method for disproportionality analysis. The signal detection criteria used in this study were the same as those reported previously: a lower limit of 95% credible interval (CrI) for IC >0.
RESULTS: The signal scores of \'\"seizures and seizure disorders not elsewhere classified (NEC)\" \"for each ALK inhibitor were crizotinib (IC: -0.00052, 95% CrI: -0.38-0.27), ceritinib (IC: 1.18, 95% CrI: 0.68-1.54), alectinib (IC: 0.68, 95% CrI: 0.19-1.02), brigatinib (IC: 1.04, 95% CrI: 0.32-1.54), and lorlatinib (IC: 0.82, 95% CrI: 0.11-1.32). On the other hand, \"generalized tonic-clonic seizures,\" \"partial simple seizures NEC,\" \"absence seizures,\" and \"partial complex seizures\" had no or few reported cases, and no signal was detected.
CONCLUSIONS: To our knowledge, this is the first report to evaluate the relationship between ALK inhibitors and seizures using post-marketing surveillance data. These results suggest that ceritinib, alectinib, brigatinib, and lorlatinib, which are highly brain-migrating drugs, are associated with seizures.